An Innovative Contract Research Organization Dedicated to Bringing Clinical Trials to Life

Dermatology

Together, Cu-Tech and Synteract create the leading dermatology CRO, with global capabilities and unparalleled access to sites and patients. Our focus on novel and required dermatology drugs provides dedicated research services unmatched in the market.
More...

General Medicine

As complexity of drug development increases, experience in one specialized area can help define strategic solutions in another. We leverage our breadth of experience in multiple areas with deep strength in focused indications to bring clinical trials to life.
More...

Neuroscience

Neuroscience-related disorders are some of the most confounding and complex to affect people. Our specialized experience in these trials aids you in developing treatments that improve functioning and help the lives of both patients and caregivers…
More...

Oncology

Like our clients, we are committed to the quest to cure cancer. But cancer is not just a single disease. It takes deep trial knowledge to know how to address its many forms. Learn how Synteract has stayed ahead of the trends leading towards new treatments…
More...

Pediatrics

Pediatric trials run the gamut of indications in drug development, but they all have primary things in common – working with children and their families requires specialized expertise and deep knowledge of regulatory requirements….
More...

Rare & Orphan Diseases

Rare and orphan diseases have unique characteristics, not the least of which is finding the right population for your trials. We know the investigators and study sites that can help to address your recruitment goals, among other challenges…
More...

9/18/2019 - 9/20/2019 : RARE Patient Advocacy Summit More...

9/17/2019: Join us for our webinar on Tuesday, September 24 at 11 a.m. EDT “Utilizing Inventive Biostatistical Methods to Enhance Rare Disease Trials.” More...

9/18/2019: Advancing Drug Development Decisions Through PK/PD & Clinical Trial Simulation - The cost of promising drugs failing in clinical development can be potentially catastrophic. Advanced PK modeling and computer assisted trial simulation can have a tremendous impact on trial design.

Synteract Blog 

9/20/2019: Our VP of Pediatric Development, Dr. Martine Dehlinger-Kremer and Feasibility Manager, Laura Deason had a wonderful time at the 2019 iCAN Research & Advocacy Summit last week!

Synteract on LinkedIn

9/20/2019: From protocol design, to study Implementation, to analysis & reporting, discover Synteract’s deep expertise and lon… https://t.co/LUpL67LtUs

Synteract Twitter Feed
x

Submit RFI / RFP

..
By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

Required

x

Contact Synteract

Tell us how to stay in touch with you:

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

Required

x

 

x

Download Resource

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

*Required

x

To complete your download, please choose an option in the Internet Explorer pop-up window at the bottom of this browser.

x

Opt In

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

*Required